| 1 |
Bacterial Adhesion / Uropathogenic E. coli |
Not established |
↓ bacterial attachment to urothelial cells |
R/G |
Reduced urinary tract bacterial colonization |
Principal clinically relevant mechanism. A-type PACs and cranberry-derived urinary metabolites contribute to anti-adhesion activity. Human RCT evidence supports prevention in selected populations, not treatment of active infection. |
| 2 |
PI3K / AKT / mTOR |
↓ pathway activation |
↔ / context-dependent |
R/G |
↓ proliferation and survival signaling |
Demonstrated with purified cranberry PACs in esophageal and other cancer models. Oral PAC exposure and clinical translation remain uncertain. |
| 3 |
Apoptosis / Autophagy / Cell Death |
↑ cell death; mechanism varies |
↔ / context-dependent |
G |
Reduced tumor cell viability |
Caspase-independent death, autophagy-associated effects, apoptosis, and necrosis have been reported depending on cell model. Apoptosis is not the universal dominant mechanism. |
| 4 |
MAPK / ERK / JNK / p38 |
↑ / ↓ context-dependent |
↔ / context-dependent |
R/G |
Growth and stress-response modulation |
Different PAC preparations and cancer models exhibit distinct MAPK responses. |
| 5 |
Cell Cycle / G2-M Arrest |
↑ cell-cycle arrest |
Uncertain |
G |
↓ cellular proliferation |
G2-M arrest reported in esophageal adenocarcinoma models using concentrated PAC fractions. |
| 6 |
NF-κB / Inflammatory Signaling |
↓ inflammatory signaling (model-dependent) |
↓ excessive inflammatory activation |
R/G |
Anti-inflammatory effects |
Reported in experimental inflammatory and cancer systems. Effects vary with extract composition and cellular context. |
| 7 |
ROS / Oxidative Stress |
↑ / ↓ context-dependent |
↓ oxidative stress in some models |
P/R |
Redox modulation |
Direct antioxidant chemistry and cellular redox effects are preparation- and concentration-dependent. Selective pro-oxidant cancer activity is not clinically established. |
| 8 |
Mitochondrial Apoptotic Signaling |
↑ BAX / BAK-associated death signaling |
Uncertain |
R/G |
Promotion of cancer cell death |
Cytochrome c, BAX, BAK, and BCL-family alterations have been observed, but canonical mitochondrial apoptosis is not consistent across models. |
| 9 |
Migration / Invasion / Adhesion |
↓ migration and invasion in selected models |
Uncertain |
G |
Potential suppression of metastatic phenotypes |
Preclinical effects; no demonstrated clinical reduction in metastasis. |
| 10 |
NRF2 / Antioxidant Response |
↔ / context-dependent |
↑ cytoprotective signaling in selected models |
R/G |
Secondary stress-response modulation |
Not an established dominant mechanism of cranberry anticancer activity. NRF2 activation can have different consequences in normal and malignant cells. |
| 11 |
Chemosensitization |
↑ sensitivity in selected experimental models |
Uncertain |
G |
Potential enhancement of cytotoxic treatments |
Preclinical only. No validated cranberry-based chemotherapy combination or clinical dose. |
| 12 |
Clinical Translation Constraint |
High extract exposure commonly required |
Generally well tolerated orally |
G |
Limited systemic anticancer translation |
Poor intact PAC absorption; extensive microbial metabolism; variable extract standardization. Cancer efficacy unproven. High intake may cause gastrointestinal effects; potential warfarin interaction and kidney-stone considerations warrant caution. |